ACT BETAHISTINE TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

BETAHISTINE HYDROCHLORIDE

可用日期:

ACTAVIS PHARMA COMPANY

ATC代码:

N07CA01

INN（国际名称）:

BETAHISTINE

剂量:

16MG

药物剂型:

TABLET

组成:

BETAHISTINE HYDROCHLORIDE 16MG

给药途径:

ORAL

每包单位数:

100

处方类型:

Prescription

治疗领域:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

產品總結:

Active ingredient group (AIG) number: 0103555003; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2018-06-12

产品特点

_ _
_Product Monograph - _
ACT
_ _
BETAHISTINE
_ _
_Page 1 of 21_
PRODUCT MONOGRAPH
PR ACT BETAHISTINE
Betahistine dihydrochloride tablets, BP
16 MG AND 24 MG
ANTI-VERTIGO AGENT
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 6J5
Date of Revision:
November 6, 2017
Submission Control No.: 210611
_ _
_Product Monograph - _
ACT
_ _
BETAHISTINE
_ _
_Page 2 of 21_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
..........................................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................11
PART II: SCIENTIFIC INFORMATION
................................................................................12
PHARMACEUTICAL INFORMATION
..........................................................................12
CLINICAL TRIALS
......................................................................................